

Benedetta Conte

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9441105/publications.pdf>

Version: 2024-02-01

25
papers

1,069
citations

687363

13
h-index

580821

25
g-index

26
all docs

26
docs citations

26
times ranked

1356
citing authors

#	ARTICLE	IF	CITATIONS
1	Anthracycline, taxane, and trastuzumab-based neoadjuvant chemotherapy in HER2-positive early breast cancer: phase II trial. <i>Tumori</i> , 2022, , 030089162110675.	1.1	1
2	Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer. <i>EBioMedicine</i> , 2022, 75, 103801.	6.1	47
3	Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 1.	5.2	331
4	Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive/HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy. <i>Clinical Cancer Research</i> , 2021, 27, 3116-3125.	7.0	9
5	Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy. <i>Npj Breast Cancer</i> , 2021, 7, 8.	5.2	14
6	Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021, 13, 1458.	3.7	17
7	Breast Cancer Surgery in the COVID-19 Pandemic: Validation of a Preventive Program for Patients and Health Care Workers. <i>In Vivo</i> , 2021, 35, 635-639.	1.3	2
8	De novo metastatic breast cancer arising in young women: review of the current evidence. <i>Clinical Breast Cancer</i> , 2021, , .	2.4	6
9	Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial. <i>International Journal of Cancer</i> , 2020, 147, 160-169.	5.1	12
10	T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study. <i>Clinical Breast Cancer</i> , 2020, 20, e181-e187.	2.4	30
11	A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. <i>Lancet Oncology</i> , The, 2020, 21, 1455-1464.	10.7	52
12	Sex Hormones and Hormone Therapy during COVID-19 Pandemic: Implications for Patients with Cancer. <i>Cancers</i> , 2020, 12, 2325.	3.7	60
13	Update on the Management of Breast Cancer during Pregnancy. <i>Cancers</i> , 2020, 12, 3616.	3.7	37
14	Frequency and spectrum of PIK3CA somatic mutations in breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 45.	5.0	175
15	Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13315.	3.4	28
16	Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study. <i>British Journal of Cancer</i> , 2020, 122, 1611-1617.	6.4	12
17	Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial. <i>European Journal of Cancer</i> , 2020, 136, 43-51.	2.8	6
18	HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2020, 84, 101965.	7.7	92

#	ARTICLE	IF	CITATIONS
19	Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and) Tj ETQq1 1 0.784314 14.99 BT /Over 1137.	3.7	22
20	Management of young women with early breast cancer. ESMO Open, 2018, 3, e000458.	4.5	15
21	Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study. Breast, 2018, 41, 51-56.	2.2	41
22	Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis. ESMO Open, 2018, 3, e000361.	4.5	49
23	Treatment-induced early menopause and the protective role of gonadotropin-releasing hormone agonists during chemotherapy. Breast Cancer Research and Treatment, 2018, 171, 245-246.	2.5	3
24	Luteinizing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer. Expert Opinion on Pharmacotherapy, 2017, 18, 1357-1362.	1.8	5
25	Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in breast cancer patients. Minerva Obstetrics and Gynecology, 2017, 69, 350-356.	1.0	3